Glavine Paul purchased $1.2M of HELP

Glavine Paul (Chief Growth Officer) purchased 100,000 shares of CYBIN INC. (HELP) at $12.47 ($1.25M total) on 2026-09-08.

Original reporting
SEC EDGAR · Glavine Paul
Published Sep 11, 2026, 1:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 1:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HELP
Bullish
medium confidence
Mentioned
$HELP
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HELPBullishLow
01

Why it matters

The insider purchase adds a positive data point for investors monitoring insider activity, but the amount is modest relative to the company's market cap.

02

Market read

Primary relevance is to HELP shareholders; broader market impact is negligible.

03

What to watch

Potential upcoming clinical data or partnership announcements not disclosed in the filing.

Relevance 7/10Novelty 7/10Timing: post‑market 2026-09-08

Background

SEC Form 4 filing reports insider transactions. CYBIN Inc. is a biotech company listed on Nasdaq under the ticker HELP.

Company-level read

Ticker impact

$HELPBullishMedium confidence
Context

Chief Growth Officer Glavine Paul bought 100,000 shares of CYBIN Inc. (HELP) for $1.247M on 2026-09-08, increasing his stake to over 4.2 million shares.

Expected impact

Potential modest upward pressure as the market digests the insider buy.

Evidence & confidence

The transaction size is over $1M, a material insider buy for a micro‑cap, but not large enough to drive a big move.

Market effects

Limited impact on the broader biotech sector; mainly a company‑specific signal.

No significant regional effect.

Minimal global relevance.

Counterpoint

The buy could be a routine portfolio rebalancing rather than a strong endorsement.

Key entities

  • Glavine Paul

    Chief Growth Officer of CYBIN Inc.

  • CYBIN Inc.

    Biotech firm trading under HELP.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HELPMed

HELP Stock Slides As Suicide Attempt Overshadows Strong Late-stage Depression Trial Data

HELP stock declined despite positive late-stage trial data for its depression drug, HLP003. The drug showed significant improvements in patients, with 56% seeing at least a 50% improvement at six weeks. Analysts like Lucid Capital raised their price target to $79, citing strong results, while Jefferies and Barclays maintained 'Buy' and 'Overweight' ratings, respectively. Retail sentiment on Stocktwits turned 'extremely bullish'.

$HELPMedAI 8/10

Helus Pharma falls 10.5% despite positive HLP003 trial

Helus Pharma (HELP) reported positive results for its experimental drug HLP003, meeting the primary endpoint in a late-stage depression trial. Despite this, shares fell 10.5% to $7.94, with three serious adverse events disclosed. Analysts noted strong efficacy and no fundamental reason for the decline. The company is also developing HLP004 for anxiety and expects to identify an HLP005 candidate in late 2027.

MedAI 8/10

Serious adverse events mar robust efficacy data for Helus’ psychedelic in major depression

Helus Pharma reported that its deuterated psilocin therapy, HLP003, significantly reduced major depressive disorder symptoms in a late-stage trial, but its stock fell due to three undisclosed serious adverse events. The trial met primary and secondary endpoints, with a 19.5-point reduction in symptoms versus 11.9 for placebo. Analysts noted the efficacy but emphasized the need for safety clarification. The company expects further trial results in 2027.

HighAI 8/10

Helus Pharma's psychedelic depression drug succeeds in late-stage study, shares jump

Helus Pharma reported that its psychedelic drug, HLP003, showed significant improvement in depression symptoms in a late-stage trial. The drug, a modified version of psilocin, is designed to be used with standard antidepressants. The company's shares rose over 20% in premarket trading. According to Helus, 56.3% of patients treated with HLP003 saw their symptoms cut by at least half, compared with 28.2% on placebo.